Darren Cai, Phd

Biography

Dr. Daqing Cai, also known as Darren, joined Legend Capital in May 2011 as a director and is now an executive director. Dr. Cai focuses on investment opportunities in the health care sector and has led LC’s investments in various companies, including Berry Genomics, Ustar, Shenogen, Cardea, BioHermes, Bionano, Hemay and Paige. Prior to joining Legend Capital, Dr. Cai worked with SBI-SDJB, a joint venture of SBI Group and Beida Jade Bird Group, as a managing director. He has also worked with Sinochem (Hong Kong) and Booz & Co. in senior management positions. He was a board member and CFO of Beijing Genomics Institute. Dr. Cai holds a PhD from University of California, Berkeley; an MBA from Yale University; and a bachelor’s degree from University of Science and Technology of China. Dr. Daqing Cai, also known as Darren, joined Legend Capital in May 2011 as a director and is now an executive director. Dr. Cai focuses on investment opportunities in the health care sector and has led LC’s investments in various companies, including Berry Genomics, Ustar, Shenogen, Cardea, BioHermes, Bionano, Hemay and Paige. Prior to joining Legend Capital, Dr. Cai worked with SBI-SDJB, a joint venture of SBI Group and Beida Jade Bird Group, as a managing director. He has also worked with Sinochem (Hong Kong) and Booz & Co. in senior management positions. He was a board member and CFO of Beijing Genomics Institute. Dr. Cai holds a PhD from University of California, Berkeley; an MBA from Yale University; and a bachelor’s degree from University of Science and Technology of China.

Research Interest

Business